Grab a bracket, pick your favorite drug names and get ready to dance: FierceMadness is here!

The 2015 Drug Name Tournament official bracket.

Voting has closed for this round. Weigh in on Round 2 >>

It's that time of year again--the time when madness of the March variety seeps into homes and offices across America and friends, families, neighbors and colleagues face off in the ultimate challenge. Pools are formed, bets are placed, and picks are submitted, all in search of that ever-elusive perfect bracket.

We're not exempt here at FiercePharmaMarketing, and we've got our own brackets underway and ready for tipoff. Only, around here, there's nary a wildcat, badger or blue devil to be found. Instead, we're eyeing a 5-12 matchup between Gilotrif and Cyramza, top-seeded-yet-vulnerable Vimizim, and tiny Rytary, which could just make a Cinderella run.

That's right--we've taken 68 recently launched drugs and squared them off against one another to determine which will walk away with this year's tournament title, and--in the spirit of the randomness that so often characterizes the NCAA's Big Dance--we're doing it based on drug name alone. 

And that's where you come in. Grab and fill out our printable bracket, check out the matchups, and scroll on down to vote below on which drug names you like the best. Check back every day to vote in each round and see which meds advance, all the way up through April 8 when we'll crown our FierceMadness 2015 Drug Name Tournament champion. And please--feel free to send us the rationale (or lack thereof) behind your choices.

Good luck!

-- Carly Helfand (email | Twitter) and Damian Garde (email | Twitter)

Round 1

No. 16 Bexsero vs. No. 16 Trumenba

Bexsero
Maker: GlaxoSmithKline
Indication: Meningitis B
Sounds like: An ancient, mythical sword

Trumenba
Maker: Pfizer
Indication: Meningitis B
Sounds like: One of Cinderella's stepsisters

No. 11 Otezla vs. No. 11 Cosentyx

Otezla
Maker: Celgene
Indication: Psoriasis
Sounds like: A lost cousin of the Jetson family

Cosentyx
Maker: Novartis
Indication: Psoriasis
Sounds like: A friendly prehistoric bird

No. 16 Contrave vs. No. 16 Saxenda

Contrave
Makers: Takeda and Orexigen
Indication: Obesity
Sounds like: A high-quality diamond cut that only a trained eye can spot

Saxenda
Maker: Novo Nordisk
Indication: Obesity
Sounds like: A distant relative of our coworker Varun

No. 11 Keytruda vs. No. 11 Opdivo

Keytruda
Maker: Merck
Indication: Cancer
Sounds like: An unwanted visitor impervious to locks

Opdivo
Maker: Bristol-Myers Squibb
Indication: Cancer
Sounds like: A covert action led by Mark Mothersbaugh

Loading...

Read more on

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.